Clinical Trials
17 trialsNCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT05364944 2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1 Terminated
NCT05459844 2025-09-05
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
Phase 3 Active not recruiting
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT00781911 2019-09-20
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00332969 2017-03-31
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
Novartis
Phase 2 Completed
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT00171886 2017-02-24
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Novartis
Phase 4 Completed
NCT00241020 2016-04-12
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 3 Completed
NCT00412061 2014-11-21
RADIANT-2
Novartis
Phase 3 Completed
NCT00690430 2013-07-30
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Novartis
Phase 3 Completed
NCT00006269 2012-05-25
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Novartis
Phase 3 Terminated
NCT00332696 2011-09-23
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Novartis
Phase 2 Completed
NCT00050635 2009-11-19
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Novartis
Phase 4 Completed